Navigation Links
Ondine Biomedical’s MRSAID(TM) Technology Demonstrates Successful Results in Reducing Surgical Site Infections
Date:12/12/2012

Vancouver, BC, Canada (PRWEB) December 12, 2012

The MRSAid photodisinfection project, an innovative non-pharmaceutical pilot program conducted over the course of 12 months at Vancouver General Hospital (VGH), has proven successful in reducing surgical site infections (SSIs) by 39 per cent, according to results released by VGH. Under this innovative project, patients undergoing major surgeries at VGH, including cardiac, spinal, orthopedic, thoracic, vascular, breast reconstruction, and neurological surgeries, were treated with MRSAid nasal decolonization therapy prior to surgery. Photodisinfection therapy combined with chlorhexidine body wipes were shown to significantly decrease a patient’s load of Methicillin resistant staphylococcus aureus (MRSA) and Methicillin sensitive staphylococcus aureus (MSSA) on their skin and in their nasal cavity. The pilot is the first of its kind and has saved the Vancouver General Hospital an estimated $1.9 million in costs associated with treating patients who develop SSIs.

“By using these two therapies in conjunction, we were able to reduce SSI occurrences by 39 per cent over the study’s duration which marks impressive gains for patient quality and safety,” said Dr. Elizabeth Bryce, Regional Medical Director, Infection Control at Vancouver Coastal Health. “Most importantly, the decrease in SSIs translates into less morbidity for our patients.”

Patients that develop infections after surgery are five times more likely to be readmitted to a hospital, and twice as likely to die. On average, SSIs require an extended hospital stay of eight days in an acute care setting, and adds hundreds of millions of dollars in additional costs to the Canadian healthcare system every year. The MRSAid photodisinfection pilot which treated more than 5000 patients saw a decrease in SSIs from 4 to 1.25 cases per month, resulting in the freeing of 533 patient beds and an addition of 138 surgeries performed. During the course of the study actual occurrences of SSIs dropped from 85 to 50 cases.

“The results of this project mark a global first for photodisinfection as a non-antibiotic approach to significant reductions in surgical site infections, one of the leading sources of healthcare associated infections,” said Carolyn Cross, Chairman and CEO of Ondine Biomedical Inc., the global leader of photodisinfection technologies. “As a partner in this initiative, we want to thank the dedicated team members at VGH for their pioneering work in the field of non-antibiotic infection control and patient safety, and for their willingness to champion innovation and change.”

Preliminary results on MRSAid nasal decolonization have been presented at two infectious disease conferences. Dr. Titus Wong and his team at Vancouver General Hospital (VGH) won the John Conly Innovation Academy Award at the AMMI - CACMID Annual Conference for their implementation of a universal nasal decolonization program.

“We are proud to be the first hospital in Canada and in North America to implement a program using this combined approach of innovative light-activated technology that will prevent patients from contracting infections post-surgery,” said Dr. Titus Wong, Medical Microbiologist, Vancouver General Hospital. “Not only will this new approach prevent infections and reduce costs, but it will also allow us to reinvest that saved money into direct patient care.”

###
About Ondine Biomedical Inc.
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratories in Bothell, Washington, USA and Minneapolis, Minnesota. Please visit the Company's website at: http://www.ondinebio.com and http://www.ondineblog.com. For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com

About Vancouver Coastal Health
Vancouver Coastal Health provides a full range of health care services, ranging from hospital treatment to community-based residential, home health, mental health and public health services. VCH is responsible for the delivery of $3 billion in care to residents of Vancouver, North Vancouver, West Vancouver, Richmond, and in the coastal mountain communities. http://www.vch.ca.

Read the full story at http://www.prweb.com/releases/OndineBio/12/prweb10229844.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Milo Biotechnology Announces FDA Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy
2. SPIE Urges Congress, President to Avoid Fiscal Cliff and Support Science and Technology to Strengthen Economy
3. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
4. A Sewage Treatment Plant Goes Underground Using In-Pipe Technology Company, Inc. Bioaugmentation
5. Bluechiip Licenses Its Technology in Deal with US Tech Company MiTeGen
6. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
7. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
8. Global Agricultural Biotechnology Industry
9. Fast forward to the past: NASA technologists test game-changing data-processing technology
10. Researchers improve technology to detect hazardous chemicals
11. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):